These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16225507)

  • 21. Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker.
    Hamilton RJ; Platz EA; Freedland SJ
    J Natl Cancer Inst; 2009 Apr; 101(8):611-2. PubMed ID: 19351913
    [No Abstract]   [Full Text] [Related]  

  • 22. Should men be screened for prostate cancer?
    Patel SM
    N C Med J; 1999; 60(5):275-7. PubMed ID: 10495656
    [No Abstract]   [Full Text] [Related]  

  • 23. [The prostate specific antigen: what can we learn from the American experience?].
    Zhao XJ
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(47):3313-5. PubMed ID: 16409833
    [No Abstract]   [Full Text] [Related]  

  • 24. PSA and prostate cancer screening: the challenge of the new millennium.
    Bjartell A
    Eur Urol; 2007 Nov; 52(5):1284-6. PubMed ID: 17720305
    [No Abstract]   [Full Text] [Related]  

  • 25. Lack of knowledge regarding prostate-specific antigen screening: is ignorance bliss?
    Hahn DL
    J Fam Pract; 1999 Sep; 48(9):679-81. PubMed ID: 10498073
    [No Abstract]   [Full Text] [Related]  

  • 26. [The PSA test--abomination or blessing? Longer follow up necessary to get an answer].
    Aus G
    Lakartidningen; 2010 Feb 17-23; 107(7):422-3. PubMed ID: 20384073
    [No Abstract]   [Full Text] [Related]  

  • 27. [Prostate-specific antigen--the most important cancer marker. Diagnostics and follow up of prostatic cancer have changed].
    Bratt O; Björk T
    Lakartidningen; 2007 Nov 14-20; 104(46):3460-4. PubMed ID: 18072615
    [No Abstract]   [Full Text] [Related]  

  • 28. Prostate cancer--the snowball is rolling.
    Ruutu M; Salo J; Nordling S; Rannikko S
    Ann Chir Gynaecol; 1999; 88(1):5-8. PubMed ID: 10230675
    [No Abstract]   [Full Text] [Related]  

  • 29. Mass screening for prostate cancer. The Swedish Council on Technology Assessment in Health Care.
    Int J Cancer Suppl; 1996; 9():1-72. PubMed ID: 8982323
    [No Abstract]   [Full Text] [Related]  

  • 30. Tumour markers in prostate cancer: EGTM recommendations. European Group on Tumour Markers.
    Anticancer Res; 1999; 19(4A):2799-801. PubMed ID: 10470244
    [No Abstract]   [Full Text] [Related]  

  • 31. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [PSA test inconvenience?].
    Drøsdal HH
    Tidsskr Nor Laegeforen; 2005 Mar; 125(5):623; author reply 623. PubMed ID: 15776048
    [No Abstract]   [Full Text] [Related]  

  • 33. Prostate-specific antigen: a misused and maligned prostate cancer biomarker.
    Thompson IM; Tangen CM; Kristal AR
    J Natl Cancer Inst; 2008 Nov; 100(21):1487-8. PubMed ID: 18957671
    [No Abstract]   [Full Text] [Related]  

  • 34. Screening for prostate cancer in 2007: the PSA era and its challenges are not over.
    Shariat SF; Karakiewicz PI
    Eur Urol; 2008 Mar; 53(3):457-60. PubMed ID: 18079050
    [No Abstract]   [Full Text] [Related]  

  • 35. Does screening with prostate/specific antigen improve outcomes?
    Ohrt D
    Minn Med; 1996 Apr; 79(4):50-1. PubMed ID: 8637494
    [No Abstract]   [Full Text] [Related]  

  • 36. Revised status of PSA testing in the early detection and treatment of prostate cancer.
    Lamb DS; Delahunt B; Nacey JN
    N Z Med J; 2011 Nov; 124(1345):13-5. PubMed ID: 22072161
    [No Abstract]   [Full Text] [Related]  

  • 37. "It's a maybe test": men's experiences of prostate specific antigen testing in primary care.
    Evans R; Edwards AG; Elwyn G; Watson E; Grol R; Brett J; Austoker J
    Br J Gen Pract; 2007 Apr; 57(537):303-10. PubMed ID: 17394734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence.
    Perrin P
    Eur Urol; 2006 Mar; 49(3):418-9. PubMed ID: 16459016
    [No Abstract]   [Full Text] [Related]  

  • 39. Prostate cancer risk assessment program: a 10-year update of cancer detection.
    Giri VN; Beebe-Dimmer J; Buyyounouski M; Konski A; Feigenberg SJ; Uzzo RG; Hanks G; Godwin AK; Chen DY; Gordon R; Cescon T; Raysor S; Watkins-Bruner D
    J Urol; 2007 Nov; 178(5):1920-4; discussion 1924. PubMed ID: 17868726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate cancer: screening and early detection.
    Tariman JD
    Adv Nurse Pract; 2006 Sep; 14(9):20. PubMed ID: 16972436
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.